# A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

*PRI Rank #1 · Topics and Trends in Most Cited Receptor Mechanisms and Signaling Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/receptor-mechanisms-and-signaling/2026/rank-1*

| Field | Value |
| --- | --- |
| Rank | #1 |
| 18m citations | 116 |
| Journal | Nature Metabolism |
| Year | 2024 |
| DOI | 10.1038/s42255-023-00966-w |
| Corresponding authors | Murielle M. Véniant |
| Institution | Amgen Research, United States |

**Ranking page:** [Topics and Trends in Most Cited Receptor Mechanisms and Signaling Papers, Class of 2026](https://pri.pepkio.com/top-papers/receptor-mechanisms-and-signaling/2026)

**Paper link:** [10.1038/s42255-023-00966-w](https://doi.org/10.1038/s42255-023-00966-w)

## Topics

AMG 133 · AMG 133 · GIPR antagonist · GLP-1 receptor agonist · bispecific molecule · anti-human GIPR monoclonal antibody · GLP-1 receptor agonist · incretin receptors · body weight reduction · metabolic markers · obese mice · cynomolgus monkeys · phase 1 clinical trial · dose-dependent weight loss · multiple ascending dose · obesity · amino acid linkers · NCT04478708

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Receptor Mechanisms and Signaling Papers, Class of 2026. https://pri.pepkio.com/top-papers/receptor-mechanisms-and-signaling/2026. Accessed 2026-07-29.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```